Antiviral asset bictegravir (GS-9883), an investigational integrase strand transfer inhibitor achieved proof-of-concept based on data from four preclinical and Phase I studies evaluating the antiviral potency, resistance profile, pharmacokinetics and safety
Patients will first need prior authorization -- prescribing clinicians will submit documentation proving the patient meets strict body mass index (BMI) and health condition requirements
doi: 10.37765/ajmc.2020.88554
This form is the most stable for shipping and long-term storage the peptide stays intact in a dry, inert state far longer than it would in solution
Tuba Tunal Akbay: Conceptualization, Supervision, Writing Original Draft
Salamun V, Jensterle M, Janez A, Vrtacnik BE (2018) Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study